ReviewClinical and experimental nephrology2006
Gene expression profiling analysis in nephrology: towards molecular definition of renal disease.
Review in Clinical and experimental nephrology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed.
- Urinary clusterin as a biomarker of human kidney disease progression and response to the endothelin receptor antagonist atrasentan: An exploratory analysis from the SONAR trial.Nature communications · 2026Trial
- Pharmacokinetics, Pharmacodynamics, and Tolerability of AZD5718, an Oral 5-Lipoxygenase-Activating Protein (FLAP) Inhibitor, in Healthy Japanese Male Subjects.Clinical drug investigation · 2021Trial
- Hypoxia inducible factor network reflects kidney disease progression in diabetes and sodium-glucose co-transporters inhibition.Signal transduction and targeted therapy · 2026Article
- Characterization of NLRP3 Inflammasome-Associated Hub Genes in the Progression of Diabetic Nephropathy.Immunity, inflammation and disease · 2026Article
- Multi-omics insights of immune cells in the risk and prognosis of idiopathic membranous nephropathy.Communications biology · 2025Article
- Disposition of orally administered atuliflapon, a novel 5-lipoxygenase-activating protein inhibitor in healthy participants.Pharmacology research & perspectives · 2024Article
- Unbiased kidney-centric molecular categorization of chronic kidney disease as a step towards precision medicine.Kidney international · 2024Article
- Glucocorticoid- and pioglitazone-induced proteinuria reduction in experimental NS both correlate with glomerular ECM modulation.iScience · 2024Article
- Precision nephrology identified tumor necrosis factor activation variability in minimal change disease and focal segmental glomerulosclerosis.Kidney international · 2023Article
- The Michigan O'Brien Kidney Research Center: transforming translational kidney research through systems biology.American journal of physiology. Renal physiology · 2022Review
- Design of FLAIR: a Phase 2b Study of the 5-Lipoxygenase Activating Protein Inhibitor AZD5718 in Patients With Proteinuric CKD.Kidney international reports · 2021Article
- Urinary EGF and MCP-1 and risk of CKD after cardiac surgery.JCI insight · 2021Article
- ShcA expression in podocytes is dispensable for glomerular development but its upregulation is associated with kidney disease.American journal of translational research · 2021Article
- Diagnostic, Prognostic, and Therapeutic Value of Non-Coding RNA Expression Profiles in Renal Transplantation.Diagnostics (Basel, Switzerland) · 2020Review
- Gene Expression Studies and Targeted Metabolomics Reveal Disturbed Serine, Methionine, and Tyrosine Metabolism in Early Hypertensive Nephrosclerosis.Kidney international reports · 2019Article
- FAR2 is associated with kidney disease in mice and humans.Physiological genomics · 2018Article
- Metabolomics and Gene Expression Analysis Reveal Down-regulation of the Citric Acid (TCA) Cycle in Non-diabetic CKD Patients.EBioMedicine · 2017Article
- Novel Biomarkers in the Diagnosis of Chronic Kidney Disease and the Prediction of Its Outcome.International journal of molecular sciences · 2017Review
- Identification of urinary exosomal noncoding RNAs as novel biomarkers in chronic kidney disease.RNA (New York, N.Y.) · 2017Article
- Tissue transcriptome-driven identification of epidermal growth factor as a chronic kidney disease biomarker.Science translational medicine · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The increase in progressive kidney disease, resulting in a constantly rising prevalence of endstage renal disease (ESRD), urgently warrants the development of more effective strategies to diagnose, prevent, and intervene in renal disease. Histological information obtained by renal biopsies (RBx) is a cornerstone of the current management of kidney disease. Renal tissue can provide critical information on the disease process not available by nontissue-based approaches. However, insight gained by conventional histopathology remains limited and additional strategies to define renal disease on a molecular level are required. The sequencing of the human genome, together with recent advances in genome-wide profiling techniques, has provided the framework for a comprehensive analysis of renal disease-associated transcriptional programs. In this review, strategies to apply these technological advances towards the analysis of RBx will be described, with special emphasis on their potential impact on clinical management, but also on their inherent limitations. Finally, an outlook towards the emerging proteomic studies of renal disease will be given.
Indexed as
Identifiers
16791393What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.